Navigation Links
Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
Date:12/13/2007

WASHINGTON, Dec. 13 /PRNewswire-USNewswire/ -- The following statement by Andrea Kavanagh, Director of the Pure Salmon Campaign, was released today:

The international journal Science will publish a study tomorrow that shows sea lice from open net salmon farms may lead to the collapse of regional wild fish stocks.

"This study confirms what we have been saying all along. Sea lice continue to wreak havoc on wild salmon populations. If outbreaks of these parasites are left unchecked, we could we run the risk of losing certain wild salmon stocks forever.

"The science from around the world is now in. We need to take immediate action and move fish farms out of the paths of migrating wild fish, before it's too late.

"Even the owner of the world's largest salmon farming company recently called to move salmon farms to save wild fish. When rigorous science is coupled with recognition of the problem from industry, there is no excuse not to act."

BACKGROUND

Open net salmon farms act as incubators for parasites and infectious diseases that can decimate the wild fish that share the same waters. Sea lice concentrated around the fish farms latch on to wild salmon as they swim past the open net pens. Adult salmon have thick scales to fight off these parasites, but juveniles lack the defenses to keep them healthy and safe. Sea lice chew on young salmon, creating open lesions that often lead to death.

The Pure Salmon Campaign (http://www.puresalmon.org) is a global project of the National Environmental Trust. It has partners in the United States, Canada, Europe, Australia and Chile all working to improve the way salmon is produced.

Contact:

Dave Bard, 202.486.4426


'/>"/>
SOURCE Pure Salmon Campaign
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
2. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
3. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
4. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
5. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
6. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
7. Actress and Mother Jennifer Garner Kicks Off American Lung Associations Faces of Influenza Awareness Campaign, Encouraging Families to Get Vaccinated Against Influenza
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
11. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Jan. 18, 2017   Spotlight Innovation Inc. ... Therapeutics plans, in the second quarter of 2017, ... roll-on intended to provide relief from chronic pain, ... analgesics. It was developed under a licensing agreement ... products derived from snake venom. Additionally, Caretta Therapeutics ...
(Date:1/18/2017)... 2017  Kratom leaves, from a South East ... used to prepare tea-like beverages and commercially manufactured ... annually to increase alertness, enhance well-being and occupational ... aches and pains. PinneyAssociates, review of the scientific ... FDA and DEA in determining the most appropriate ...
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, announces ... DMT210, in a Phase 2 acne rosacea study. ... downregulate the proinflammatory cytokines in the skin responsible ... rosacea. This clinical trial, DMT210-003, ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... Park ... financial planning services to families and business owners in the greater Kansas City ... children with developmental disabilities. , The Lakemary Center is a comprehensive educational resource ...
(Date:1/18/2017)... ... 18, 2017 , ... Michael J. Hennessy Associates, Inc., (MJH), ... for Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael J. Hennessy, Jr. ... through thought leader interaction in, live video and interactive digital platforms. , In ...
(Date:1/18/2017)... ... January 18, 2017 , ... Floundering on New Year’s resolutions? Need an excuse ... for a reset. The U.S. Apple Association agrees and recommends starting each day ... that contribute to heart disease. , The U.S. Apple Association – which represents apple ...
(Date:1/17/2017)... California (PRWEB) , ... January 17, 2017 , ... ... have a point of difference. Eden Activewear is a stand-out company for several ... are exclusively online and only manufacture on demand, this is called 'Agile' manufacturing ...
(Date:1/17/2017)... ... January 17, 2017 , ... SunView Software’s Service Smart Technology has ... the Year. , Each year, Pink Elephant recognizes a new product or ... address a specific business problem or opportunity. The award highlights original innovations that were ...
Breaking Medicine News(10 mins):